ConductScience.org, home

Comparison · NCT03572049-sae

SUBA Itraconazole vs Conventional Itraconazole: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. SUBA Itraconazole vs Conventional Itraconazole: serious adverse events. Trial comparisons, record NCT03572049-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03572049-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.09520.03770.221wilson
Risk in group 20.2610.1560.403wilson
Risk difference, group 1 minus group 2-0.166-0.319-0.00216newcombe hybrid score
Risk ratio, group 1 over group 20.3650.1281.04log
Odds ratio, group 1 over group 20.2980.08781.01log
Number needed to treat, for one fewer participant with a serious adverse event on SUBA Itraconazole than on Conventional Itraconazole6.043.14464from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1SUBA Itraconazole
Stage 1: Day 1-3 two 65 mg capsules three times daily with food. Days 4-42 two 65 mg capsules twice daily with food.~Stage 2 : Days 43-180 two 65 mg capsules twice daily with food~SUBA itraconazole: SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.
442EG000
Group 2Conventional Itraconazole
Stage 1: Day 1-3 two 100 mg capsules three times daily with food. Days 4-42 two 100 mg capsules twice daily with food.~Stage 2 : Days 43-180 two 100 mg capsules twice daily with food~Conventional itraconazole: Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.
1246EG001

Harm

What it counts
Total, serious adverse events
Time frame
Data regarding all adverse events were collected over 180 days (approximately 6 months).

Source ClinicalTrials.gov

Trial

Title
Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
NCT number
NCT03572049
Phases
PHASE2, PHASE3
Conditions
Invasive Fungal Infections
Interventions
SUBA itraconazole, Conventional itraconazole
Lead sponsor
University of Alabama at Birmingham
Results first posted
2022-10-06

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03572049-sae